Welcome to the QRISK®3-2017 risk calculator
Welcome to the QRISK®3-2017 Web Calculator. You can use this calculator to work out your risk of developing a heart attack or stroke over the next 10 years by answering some simple questions.
The QRISK®3 algorithm has been developed by doctors and academics working in the UK National Health Service and is based on routinely collected data from many thousands of GPs across the country who have freely contributed data to the QResearch database for medical research.
QRISK®3 has been developed for the UK population, and is intended for use in the UK. All medical decisions need to be taken by a patient in consultation with their doctor. The authors and the sponsors accept no responsibility for clinical use or misuse of this score.
The science underpinning QRISK®3 has been published in the BMJ -- see the publications tab for details.
What is the difference between QRISK®3 and QRISK®2?
QRISK®3 includes more factors than QRISK®2 to help enable doctors to identify those at most risk of heart disease and stroke.
- Chronic kidney disease, which now includes stage 3 CKD
- Systemic lupus erythematosus (SLE)
- atypical antipsychotics
- severe mental illness
- erectile dysfunction
- a measure of systolic blood pressure variability
Has QRISK®3 been validated?
Yes. QRISK®3 has been validated on a separate group of practices from that used to develop the score and the performance is very good. See the academic paper for more details.
Why change the name from QRISK®2 to QRISK®3?
It's the same science and team behind the score, and the way that we intend it to be used remains exactly the same. In many ways it is very similar to our usual annual updates -- however, we thought that as we are introducing several new parameters, we'd upgrade its major version number.
What will now happen to QRISK®2?
QRISK®2-2017 will be the last version of QRISK®2 that we will produce. QRISK®3 will be the standard version of QRISK® shipped in our software development kits in 2018, so all implementations will become QRISK®3 in due course.